NIDDK Funding Opportunity

R43/R44 Small Business Innovation Research Grants (SBIR)

Lead Optimization and Preclinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (R43/R44)

The goal of this Funding Opportunity Announcement (FOA) is to support lead optimization and preclinical development of new therapies for diseases within the mission of the NIDDK with the SBIR program. SBIR Phase I projects under this FOA supportpreliminary steps in the process for lead optimization or preclinical development of therapeutics. SBIR Phase II supports lead optimization and preclinical development of lead candidates, and projects must be sufficiently advanced such that an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) can be submitted by the end of a SBIR Phase II or IIB project. Applications are expected to have defined Milestones and Timelines detailing how the project will move forward with identified key Go / No Go decision points.

Full AnnouncementPA-17-130
Open Date3/5/2017
Letter of Intent Due Date
Not Applicable
Application Due Date
Standard dates apply, by 5:00 PM local time of applicant organization. *** Note new SBIR/STTR Standard Due Dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Program ContactGuillermo Arreaza-Rubin, M.D.
Opportunity Resources
Small Business Opportunities

Click outside of the light box to close the box.